ADTX — Aditxt Share News
0.000.00%
Last trade - 00:00- $2.10m
- $3.24m
- $0.00m
Brief: Aditxt Provides Updates On Its Growth Vision For Bitxbio™, Planned Digital Asset Treasury, Pearsanta’S Planned IPO, And Evofem’S Plan To Regain A National Listing
Brief: Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting
Brief: Aditxt Inc - Adimune Plans FDA Submission For Trials In Early 2026
Brief: Aditxt to resale up to 50 million shares to Seven Knots from time to time - SEC filing
Brief: Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board Of Directors
CEO Of Adimune, And Chris Mitton, President Of Pearsanta, Will Join Aditxt Weekly Update On June 6
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics
Brief: Aditxt Subsidiary Pearsanta Receives Irb Approval To Initiate Clinical Study Of Blood-Based Diagnostic For Endometriosis With Patient Enrollment Planned To Begin In May 2025
Brief: Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials
Brief: Aditxt Enters Securities Purchase Agreement With Evofem Biosciences - SEC Filing
Brief: Aditxt Regains Compliance With Nasdaq Listing Requirements
Brief: Appili President And CEO, Don Cilla To Join Aditxt CEO, Amro Albanna For Aditxt Weekly Update On April 4, 2025
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign
U.S. STOCKS ON THE MOVE-Ralph Lauren, Gold miners, Aditxt
Aditxt more than doubles after Appili takeover deadline extended
Brief: Appili Therapeutics Announces Submission Of US Federal Government Funding Proposals And Provides Corporate And Aditxt Transaction Update
Brief: Aditxt Co's Unit Pearsanta Engaged Dominari Securities Llc As Lead Underwriter For Pearsanta's Planned IPO
Brief: Aditxt’S Board Of Directors Unanimously Approve Positioning Pearsanta For IPO To Support Global Launch Of Its Early Cancer Detection Platform